Friday, September 11, 2026
30 C
Bengaluru

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in Indian Pharma? Executive Summary The Indian Pharmaceutical Market (IPM) entered 2026 with strong momentum, delivering approximately 11% year-on-year growth in February 2026. The narrative appears compelling: chronic therapies are expanding, volumes are stabilizing, and GLP-1 agonists are positioning India within the global specialty drug landscape. However,…

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

Topics

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...
spot_img

Related Articles

spot_imgspot_img